FeesSafety
Pluang+

AI reduces website visits as a key B2B metric, pushing marketers to build ongoing audience relationships instead.

Market News
09 Nov 2026, 15:02 WIB
PRNewsWire
View Source
Neutral
AI reduces website visits as a key B2B metric, pushing marketers to build ongoing audience relationships instead.

AI-generated summaries are decreasing traditional website visits and clicks, challenging B2B marketers who rely on traffic as a success metric. With bots accounting for over half of web traffic and AI answers often providing information without clicks, marketers must focus on identifying real human visitors and nurturing them through newsletters and direct engagement. This shift means building long-term relationships with verified prospects is more valuable than just counting visits, especially in B2B where purchase decisions take time.

The story on AI Search impacting web traffic offers context alongside Pluang's Technology sector data. For readers following this sector, here is Pluang's market snapshot as of Nov 09, 2026 19:42 WIB: out of 150 priced stocks, 100 rose and 41 fell. CLS (Celestica Inc) gained 3.49% to USD 213.90 with a typical hold time of 35 days, contrasting with CIFR (Cipher Mining Inc) which dropped 3.36% to USD 6.33 and a shorter hold time of 17 days. VERI (Veritone Inc) also rose 3.43% to USD 0.50 with a 17-day hold time.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
1 hour ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
2 hours ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
2 hours ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
2 hours ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App